Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy

Transplant International

Volumn 25, Issue 5, 2012, Pages 506-517

  Morath, Christian ^a   Beimler, Jörg ^a   Opelz, Gerhard ^a   Scherer, Sabine ^a   Schmidt, Jan ^a   MacHer Goeppinger, Stephan ^a   Klein, Katrin ^a   Sommerer, Claudia ^a   Schwenger, Vedat ^a   Zeier, Martin ^a   Süsal, Caner ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

antibody mediated rejection; immunoadsorption; kidney transplantation; living donor; positive crossmatch

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CD20 ANTIBODY; CREATININE; HEPARIN; HLA ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NYSTATIN; PENTAMIDINE; PROTEIN; RITUXIMAB; SULFAMETHOXAZOLE; TACROLIMUS; THYMOCYTE ANTIBODY; TRIMETHOPRIM;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD GROUP TYPING; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DESENSITIZATION; DRUG DOSE REDUCTION; FEMALE; FLUORESCENCE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOADSORPTION; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; MYCOSIS; PATIENT MONITORING; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD COMPONENT REMOVAL; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84859729515     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01447.x     Document Type: Article

References (34)

1. Jordan SC, Pescovitz MD,. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006; 1: 421.
2. Süsal C, Morath C,. Current approaches to the management of highly sensitized kidney transplant patients. Tissue Antigens 2011; 77: 177.
3. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
4. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S,. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
5. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
6. Thielke JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009; 87: 268.
7. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9: 536.
8. Morath C, Beimler J, Opelz G, et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 2010; 90: 645.
9. Schwenger V, Morath C,. Immunoadsorption in nephrology and kidney transplantation. Nephrol Dial Transplant 2010; 25: 2407.
10. Wahrmann M, Schiemann M, Marinova L, et al. Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. Nephrol Dial Transplant 2011 (epub ahead of print).
11. Gjorstrup P, Berntorp E, Larsson L, Nilsson IM,. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption. Vox Sang 1991; 61: 244.
12. Belak M, Borberg H, Jimenez C, Oette K,. Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci 1994; 15: 419.
13. Dittrich E, Schmaldienst S, Derfler K,. [Plasma exchange and immunoadsorption]. Wien Klin Wochenschr 2007; 119: 39.
14. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
15. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
16. Bartel G, Wahrmann M, Regele H, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010; 10: 2033.
17. Rogers NM, Eng HS, Yu R, et al. Desensitization for renal transplantation: depletion of donor-specific anti-HLA antibodies, preservation of memory antibodies, and clinical risks. Transplant Int 2011; 24: 21.
18. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208.
19. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542.
20. Qiu J, Cai J, Terasaki PI, El-Awar N, Lee JH,. Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads. Transplantation 2005; 80: 1511.
21. Kinukawa T, Kato M, Terasaki PI, Ozawa M,. Retrospective antibody analysis of thirty patients with kidney graft failure. Clin Transplant 2006; 291.
22. van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85: 1086.
23. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC,. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008; 85: 1200.
24. Mai ML, Ahsan N, Wadei HM, et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009; 87: 227.
25. Süsal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a collaborative transplant study report. Transplantation 2011; 91: 883.
26. Cai J, Terasaki PI, Anderson N, Lachmann N, Schonemann C,. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88: 226.
27. Niederhaus SV, Muth B, Lorentzen DF, et al. Luminex-based desensitization protocols: the University of Wisconsin initial experience. Transplantation 2011; 92: 12.
28. Lefaucheur C, Antoine C, Suberbielle C, Glotz D,. Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant 2011; 11: 1592.
29. Opelz G, Döhler B,. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008; 86: 371.
30. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
31. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
32. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56.
33. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
34. Schmaldienst S, Mullner M, Goldammer A, et al. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology (Oxford) 2001; 40: 513.